Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02073487 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel
A Phase 2 study, sponsored by The Methodist Hospital Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT02073487 is a Phase 2 study that has completed, run by The Methodist Hospital Research Institute. The registered enrollment target is 32 participants.
The verdict
NCT02073487, a Phase 2 study, has completed, sponsored by The Methodist Hospital Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a randomized, open label Phase II neoadjuvant study comparing the efficacy and safety of trastuzumab emtansine (T-DM1) plus lapatinib (L)followed by abraxane (A) versus trastuzumab plus pertuzumab followed by paclitaxel in patients with HER2-overexpressing breast cancer.
Interventions
- DRUG Trastuzumab
- DRUG Paclitaxel
- DRUG T-DM1
- DRUG Abraxane
- DRUG Lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2014-02 |
| Est. Completion | 2019-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02073487
The ClinicalTrials.gov registry entry for NCT02073487 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Trastuzumab is the first listed.
NCT02073487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02073487 about?
NCT02073487 is a clinical study titled "Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel". This is a randomized, open label Phase II neoadjuvant study comparing the efficacy and safety of trastuzumab emtansine (T-DM1) plus lapatinib (L)followed by abraxane (A) versus trastuzumab plus pertuzumab followed by paclitaxel in patients with HER2-overexpressing breast cancer.
What is the current status of trial NCT02073487?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2014-02. Estimated completion is 2019-01.
What interventions are being tested in trial NCT02073487?
The interventions under investigation include: Trastuzumab (DRUG), Paclitaxel (DRUG), T-DM1 (DRUG), Abraxane (DRUG), Lapatinib (DRUG).
Who is sponsoring clinical trial NCT02073487?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.